Table 2.
Compound | Y[a] | PR transactivation assay | Metabolic stability assay | ||
---|---|---|---|---|---|
IC50 [nm] | Efficacy [%] | F max Human [%] | F max Rat [%] | ||
4 | H | 0.17 | 90 | 79 | 88 |
5 | 0.01 | 99 | 31 | 54 | |
6 | 0.01 | 100 | 28 | 53 | |
7 | 0.05 | 100 | 66 | 61 | |
8 | 0.04 | 100 | 8 | 47 | |
9 | 25 | 99 | 98 | n.d.[b] | |
10 | 14 | 99 | n.d.[b] | n.d.[b] | |
11 | 0.09 | 100 | 97 | 97 | |
12 | 0.90 | 100 | 75 | 95 | |
13 | 1.4 | 99 | 39 | 60 |
[a] Substituent at the 4′ position of the 11β‐phenyl ring. [b] Not determined.